+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antibacterial Drugs Market by Drug Class, Route of Administration, Molecule Type, Spectrum of Activity, Mechanism of Action, Formulation, Indication, Point of Sale, Distribution Channel - Global Forecast 2026-2032- Product Image
Antibacterial Drugs Market by Drug Class, Route of Administration, Molecule Type, Spectrum of Activity, Mechanism of Action, Formulation, Indication, Point of Sale, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Antibacterial Drugs Market by Drug Class, Route of Administration, Molecule Type, Spectrum of Activity, Mechanism of Action, Formulation, Indication, Point of Sale, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904673
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antibacterial Drugs Market is projected to reach USD 56.47 Billion in 2026. It is expected to continue growing at a CAGR of 4.69%, reaching USD 74.53 Billion by 2032.

The antibacterial drugs industry remains a critical pillar of global healthcare as hospitals, outpatient providers, and public health agencies respond to rising antimicrobial resistance, acute bacterial infections, surgical prophylaxis needs, and infection risks in aging and immunocompromised populations.

WHO recognizes antimicrobial resistance as a major global public health threat, and the 2019 Global Research on Antimicrobial Resistance analysis estimated 1.27 million deaths directly attributable to bacterial AMR and 4.95 million deaths associated with bacterial AMR. This makes antibacterial drug discovery, responsible access, antimicrobial stewardship, and resilient antibiotic supply chains central to market competitiveness and public health preparedness.

Transformative Shifts in the Antibacterial Drug Landscape

The antibacterial drugs market is shifting from high-volume broad-spectrum use toward evidence-led, precision antibacterial therapy. Hospitals increasingly prioritize antimicrobial stewardship, rapid diagnostics, susceptibility testing, pathogen surveillance, and real-world outcome data to guide formulary decisions and reduce inappropriate prescribing.

Research and commercialization are concentrating on multidrug-resistant Gram-negative pathogens, methicillin-resistant Staphylococcus aureus, complicated urinary tract infections, hospital-acquired and ventilator-associated pneumonia, bloodstream infections, and combination regimens. Pull incentives, subscription-style reimbursement pilots, and public-private partnerships are gaining importance as traditional antibiotic revenue models remain constrained by short treatment durations and stewardship controls.

Cumulative Impact of Artificial Intelligence on Antibacterial Drugs

Artificial intelligence is increasingly used across antibacterial drug discovery, including target identification, compound screening, molecule optimization, retrosynthesis planning, resistance prediction, clinical trial design, and pharmacovigilance. AI can analyze large chemical libraries, genomic datasets, and microbiology data faster than conventional workflows, improving early-stage prioritization for antibacterial drug development.

The strongest impact comes when AI is paired with high-quality wet-lab validation, curated resistance data, pharmacokinetic and pharmacodynamic modeling, and clinically relevant pathogen panels. Industry leaders are also applying AI to hospital surveillance, demand planning, safety monitoring, and patient stratification while maintaining strict governance around bias, privacy, explainability, and regulatory transparency.

Key Regional Insights for Antibacterial Drugs

Asia-Pacific is a major growth engine for antibacterial drugs due to high infection burden, expanding hospital infrastructure, large generic manufacturing capacity, and rising healthcare access across China, India, Japan, South Korea, Australia, and ASEAN markets. The region is also central to global active pharmaceutical ingredient production and increasingly important for surveillance-led antimicrobial resistance policy. North America remains a premium innovation hub supported by FDA antibacterial development pathways, CDC resistance surveillance, advanced diagnostics adoption, infectious disease research networks, and hospital stewardship programs.

Europe combines mature antibiotic stewardship with EMA regulatory oversight, ECDC surveillance, national action plans, and procurement models that increasingly value access to novel antimicrobials. Latin America, led by Brazil and Mexico, shows sustained demand for affordable antibacterial drugs, stronger hospital infection control, and improved access to quality-assured therapies. The Middle East is supported by GCC healthcare investment, centralized procurement, tertiary-care expansion, and medical tourism, while Africa reflects high unmet need, infectious disease burden, limited laboratory capacity in several settings, and access-focused opportunities aligned with WHO antimicrobial resistance action plans.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are shaped by diverse healthcare systems, rising hospital capacity, cross-border health security priorities, and the need to balance antimicrobial access with stronger stewardship. The GCC benefits from well-funded public healthcare systems, centralized tenders, antimicrobial resistance action plans, and growing demand for advanced hospital anti-infective therapies, particularly in tertiary care settings.

The European Union is defined by harmonized regulation, coordinated AMR surveillance, pharmacovigilance, and strong stewardship policies that influence antibacterial prescribing and procurement. BRICS countries offer scale through large populations, domestic manufacturing depth, and substantial infection-management needs, while also increasing regulatory scrutiny and surveillance capacity. G7 markets drive innovation, clinical guidelines, reimbursement experimentation, and global health financing discussions, while NATO countries increasingly view antibiotic access, medical readiness, stockpiling, and pharmaceutical supply resilience as strategic security priorities.

Key Country Insights in Major Antibacterial Drug Markets

The United States leads in antibacterial innovation, infectious disease trials, advanced hospital purchasing, CDC surveillance, and FDA regulatory pathways, while Canada emphasizes stewardship, quality use, and equitable access through publicly funded healthcare systems. Mexico and Brazil present major Latin American opportunities through high patient volumes, expanding institutional demand, and ongoing efforts to strengthen antimicrobial controls and hospital infection prevention. The United Kingdom, Germany, France, Italy, and Spain are mature European antibacterial drug markets shaped by stewardship, health technology assessment, national prescribing guidelines, hospital formularies, and surveillance-based policy.

Russia retains significant demand for hospital and community antibacterial therapy, supported by domestic treatment needs and public health monitoring. China and India combine large infection burdens, domestic manufacturing strength, expanding healthcare access, and increasing regulatory oversight of antibiotic quality and use. Japan, Australia, and South Korea are advanced markets with strong quality standards, aging populations, active antimicrobial resistance strategies, and demand for differentiated antibacterial therapies targeting resistant bacterial infections in hospital and specialty-care settings.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize antibacterial candidates with clear clinical differentiation, activity against WHO and CDC priority resistant pathogens, defensible intellectual property, and evidence packages that demonstrate mortality, cure-rate, length-of-stay, safety, or resistance-management value. Linking drugs with rapid diagnostics, susceptibility testing, and stewardship protocols can strengthen adoption and support responsible use.

Organizations should diversify active pharmaceutical ingredient sourcing, invest in quality systems, strengthen shortage-risk monitoring, expand real-world evidence programs, and engage early with regulators, payers, hospitals, and public health agencies. Partnerships with academic groups, diagnostics developers, government funders, and global health organizations can reduce development risk while supporting responsible antibacterial access across high-income and resource-limited settings.

Research Methodology

The executive summary is developed through a structured research methodology combining secondary research, expert interpretation, and cross-validation of public health, regulatory, clinical, and commercial sources. Core references include WHO, CDC, ECDC, FDA, EMA, national health agencies, peer-reviewed journals, clinical trial registries, antimicrobial resistance surveillance programs, treatment guidelines, and public procurement information.

The analysis evaluates antibacterial drug classes, pathogen priorities, regional healthcare dynamics, reimbursement trends, manufacturing risks, stewardship policies, access considerations, and AI-enabled innovation. Insights are triangulated to avoid unsupported claims and to present an evidence-based view of market direction, competitive positioning, regulatory priorities, and strategic opportunities without relying on market sizing or forecast assumptions.

Conclusion

The antibacterial drugs market is entering a decisive period where antimicrobial resistance, hospital infection control, public health preparedness, and pharmaceutical innovation intersect. Demand remains durable, but commercial success depends on solving real clinical problems, improving patient outcomes, and preserving antibiotic effectiveness rather than relying on volume growth alone.

Organizations that combine novel mechanisms, reliable supply, responsible promotion, diagnostic integration, stewardship alignment, and credible real-world evidence will be best positioned. As AI, surveillance, reimbursement reform, and regional access strategies mature, the sector will reward participants that deliver measurable value to patients and health systems while protecting the long-term utility of antibacterial therapy.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Antibacterial Drugs Market, by Drug Class
7.1. Aminoglycosides
7.1.1. Amikacin
7.1.2. Gentamicin
7.1.3. Streptomycin
7.1.4. Tobramycin
7.2. Beta-Lactams
7.2.1. Carbapenems
7.2.2. Cephalosporins
7.2.3. Monobactams
7.2.4. Penicillins
7.3. Macrolides
7.4. Quinolones
7.5. Sulfonamides
7.6. Tetracyclines
8. Antibacterial Drugs Market, by Route Of Administration
8.1. Oral
8.2. Parenteral
8.3. Topical
9. Antibacterial Drugs Market, by Molecule Type
9.1. Branded
9.2. Generic
10. Antibacterial Drugs Market, by Spectrum Of Activity
10.1. Broad Spectrum
10.2. Narrow Spectrum
11. Antibacterial Drugs Market, by Mechanism of Action
11.1. Cell Wall Inhibitors
11.2. DNA Inhibitors
11.3. Protein Synthesis Inhibitors
12. Antibacterial Drugs Market, by Formulation
12.1. Capsules
12.2. Liquid
12.3. Powder
12.4. Tablets
13. Antibacterial Drugs Market, by Indication
13.1. Respiratory Infections
13.2. Sexually Transmitted Infections
13.3. Skin Infections
13.4. Urinary Tract Infections
14. Antibacterial Drugs Market, by Point of Sale
14.1. Over-The-Counter Drugs
14.2. Prescription Drugs
15. Antibacterial Drugs Market, by Distribution Channel
15.1. Offline
15.1.1. Hospital Pharmacy
15.1.2. Retail Pharmacy
15.2. Online
16. Asia-Pacific Antibacterial Drugs Market
17. North America Antibacterial Drugs Market
18. Latin America Antibacterial Drugs Market
19. Europe Antibacterial Drugs Market
20. Middle East Antibacterial Drugs Market
21. Africa Antibacterial Drugs Market
22. ASEAN Antibacterial Drugs Market
23. GCC Antibacterial Drugs Market
24. European Union Antibacterial Drugs Market
25. BRICS Antibacterial Drugs Market
26. G7 Antibacterial Drugs Market
27. NATO Antibacterial Drugs Market
28. United States Antibacterial Drugs Market
29. China Antibacterial Drugs Market
30. Germany Antibacterial Drugs Market
31. India Antibacterial Drugs Market
32. United Kingdom Antibacterial Drugs Market
33. Canada Antibacterial Drugs Market
34. Japan Antibacterial Drugs Market
35. France Antibacterial Drugs Market
36. Brazil Antibacterial Drugs Market
37. Italy Antibacterial Drugs Market
38. South Korea Antibacterial Drugs Market
39. Mexico Antibacterial Drugs Market
40. Australia Antibacterial Drugs Market
41. Spain Antibacterial Drugs Market
42. Russia Antibacterial Drugs Market
43. Competitive Landscape
43.1. Market Concentration Analysis, 2025
43.1.1. Concentration Ratio (CR)
43.1.2. Herfindahl Hirschman Index (HHI)
43.2. Recent Developments & Impact Analysis, 2025
43.3. Product Portfolio Analysis, 2025
43.4. Benchmarking Analysis, 2025
44. Company Profiles
44.1. Abbott Laboratories
44.2. AbbVie Inc.
44.3. Allecra Therapeutics GmbH
44.4. Astellas Pharma Inc.
44.5. AstraZeneca PLC
44.6. Bausch Health Companies Inc.
44.7. Bayer AG
44.8. Bristol-Myers Squibb Company
44.9. Century Pharmaceuticals Ltd.
44.10. Cipla Limited
44.11. Debiopharm Group
44.12. Dr. Reddy’s Laboratories Ltd.
44.13. Eli Lilly and Company
44.14. Entasis Therapeutics by Innoviva, Inc.
44.15. F. Hoffmann-La Roche AG
44.16. GlaxoSmithKline PLC
44.17. Glenmark Pharmaceuticals Limited
44.18. Hikma Pharmaceuticals PLC
44.19. Iterum Therapeutics PLC
44.20. Johnson & Johnson Services, Inc.
44.21. Kyorin Pharmaceutical Co., Ltd.
44.22. Lupin Limited
44.23. Melinta Therapeutics LLC
44.24. Merck & Co., Inc.
44.25. Novartis AG
44.26. Pfizer Inc.
44.27. Sanofi S.A.
44.28. Sumitomo Pharma Co., Ltd.
44.29. Sun Pharmaceutical Industries Limited
44.30. Taj Pharmaceuticals Limited
44.31. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL ANTIBACTERIAL DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ANTIBACTERIAL DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ANTIBACTERIAL DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ANTIBACTERIAL DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANTIBACTERIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL ANTIBACTERIAL DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
FIGURE 25. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 27. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2025 VS 2032 (%)
FIGURE 29. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 31. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 39. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 41. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 43. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 51. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 52. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 53. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 54. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 55. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 56. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. FRANCE ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 65. ITALY ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 66. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 67. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 68. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 69. SPAIN ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 70. RUSSIA ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTIBACTERIAL DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIBACTERIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL ANTIBACTERIAL DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL AMIKACIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL AMIKACIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL AMIKACIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GENTAMICIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GENTAMICIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GENTAMICIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL STREPTOMYCIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL STREPTOMYCIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL STREPTOMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL TOBRAMYCIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL TOBRAMYCIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL TOBRAMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL BETA-LACTAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL BETA-LACTAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL BETA-LACTAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CARBAPENEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CARBAPENEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CARBAPENEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CEPHALOSPORINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CEPHALOSPORINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL MONOBACTAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL MONOBACTAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL MONOBACTAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL MACROLIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL MACROLIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL MACROLIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL QUINOLONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL QUINOLONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL QUINOLONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL SULFONAMIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL SULFONAMIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL SULFONAMIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL TETRACYCLINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL TETRACYCLINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL TETRACYCLINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL BROAD SPECTRUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL BROAD SPECTRUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL BROAD SPECTRUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL NARROW SPECTRUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL NARROW SPECTRUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL NARROW SPECTRUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL CELL WALL INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL CELL WALL INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CELL WALL INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL DNA INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL DNA INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL DNA INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL PROTEIN SYNTHESIS INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL PROTEIN SYNTHESIS INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL PROTEIN SYNTHESIS INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL LIQUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL LIQUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL LIQUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL POWDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL POWDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL POWDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL SKIN INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL SKIN INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL SKIN INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL OVER-THE-COUNTER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL OVER-THE-COUNTER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL OVER-THE-COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 144. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 149. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 152. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 153. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 154. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
TABLE 155. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 156. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 157. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 158. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 159. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
TABLE 160. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 161. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 162. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 163. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
TABLE 164. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 165. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 166. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 167. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
TABLE 168. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 169. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 170. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 171. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 172. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
TABLE 173. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 174. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 175. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 176. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
TABLE 177. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 178. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 179. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 180. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
TABLE 181. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 182. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 183. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 184. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 185. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
TABLE 186. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 187. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 188. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 189. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
TABLE 190. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 191. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 192. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 193. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
TABLE 194. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 195. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 196. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 197. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 198. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
TABLE 199. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 200. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 201. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 202. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
TABLE 203. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 204. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 205. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 206. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
TABLE 207. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 208. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 209. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 210. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 211. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
TABLE 212. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 213. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 214. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 215. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
TABLE 216. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 217. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 218. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 219. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
TABLE 220. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 221. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 222. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 223. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 224. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
TABLE 225. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 226. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 227. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 228. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
TABLE 229. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 230. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 231. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 232. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
TABLE 233. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 234. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 247. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 248. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 249. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 250. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
TABLE 251. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 252. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 253. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 254. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
TABLE 255. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 256. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 257. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 258. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
TABLE 259. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 260. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 261. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 262. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 263. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
TABLE 264. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 265. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 266. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 267. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
TABLE 268. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 269. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 270. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 271. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
TABLE 272. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 273. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 274. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 275. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 276. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
TABLE 277. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 278. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 279. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 280. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
TABLE 281. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 282. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 283. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 284. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
TABLE 285. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 286. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 287. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 288. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 289. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
TABLE 290. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 291. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 292. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 293. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
TABLE 294. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 295. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 296. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 297. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
TABLE 298. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 299. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 300. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 301. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 302. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
TABLE 303. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 304. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 305. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 306. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
TABLE 307. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 308. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 309. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 310. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
TABLE 311. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 312. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 313. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 314. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 315. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
TABLE 316. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 317. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 318. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 319. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
TABLE 320. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 321. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 322. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 323. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
TABLE 324. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 325. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 326. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 327. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 328. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
TABLE 329. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 330. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 331. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 332. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
TABLE 333. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 334. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 335. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 336. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
TABLE 337. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 338. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 339. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 340. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 341. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
TABLE 342. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 343. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 344. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 345. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
TABLE 346. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 347. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 348. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 349. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
TABLE 350. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 351. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 352. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 353. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 354. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
TABLE 355. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
TABLE 356. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 357. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 358. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2032 (USD MILLION)
TABLE 359. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 360. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 361. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 362. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2032 (USD MILLION)
TABLE 363. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 364. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE

Companies Mentioned

The companies featured in this Antibacterial Drugs market report include:
  • Abbott Laboratories
  • AbbVie Inc.
  • Allecra Therapeutics GmbH
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Century Pharmaceuticals Ltd.
  • Cipla Limited
  • Debiopharm Group
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Entasis Therapeutics by Innoviva, Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Iterum Therapeutics PLC
  • Johnson & Johnson Services, Inc.
  • Kyorin Pharmaceutical Co., Ltd.
  • Lupin Limited
  • Melinta Therapeutics LLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages182
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 56.47 Billion
Forecasted Market Value ( USD ) by 2032 $ 74.53 Billion
Compound Annual Growth Rate4.6%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Antibiotics Market by Drug Class, Type, Spectrum, Route of Administration, Application, Distribution Channel - Global Forecast 2026-2032 - Product Image

Antibiotics Market by Drug Class, Type, Spectrum, Route of Administration, Application, Distribution Channel - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Agricultural Antibacterials Market - Global Forecast 2026-2032 - Product Image

Agricultural Antibacterials Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Antibacterial Drugs - Global Strategic Business Report - Product Image

Antibacterial Drugs - Global Strategic Business Report

  • Report
  • 244 Pages
  • Global
From
Antibacterial Drugs Market Insights, Competitive Landscape, and Market Forecast - 2033 - Product Image

Antibacterial Drugs Market Insights, Competitive Landscape, and Market Forecast - 2033

  • Report
  • 200 Pages
  • Global
From
Antibacterial Drugs Market Outlook 2026-2034: Market Share and Growth Analysis by Drug Class, Drug Mechanism, Spectrum of Activity, Route of Administration - Product Image

Antibacterial Drugs Market Outlook 2026-2034: Market Share and Growth Analysis by Drug Class, Drug Mechanism, Spectrum of Activity, Route of Administration

  • Report
  • 160 Pages
  • Global
From

About the Market

Aminoglycosides are a class of antibiotics used to treat a wide range of bacterial infections. They are derived from natural sources, such as soil bacteria, and are effective against Gram-negative bacteria. Aminoglycosides work by inhibiting protein synthesis in bacteria, which prevents them from replicating and spreading. They are often used in combination with other antibiotics to treat more serious infections. Aminoglycosides are commonly used in hospitals and other healthcare settings, as well as in the treatment of serious infections in the community. They are also used in veterinary medicine. The aminoglycosides market is highly competitive, with a number of companies offering a range of products. Major players in the market include Merck & Co., Pfizer, Sanofi, Novartis, and Bayer. Other companies in the market include Allergan, AstraZeneca, GlaxoSmithKline, and Eli Lilly. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.